Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV.
about
Managing dyslipidemia in HIV/AIDS patients: challenges and solutionsLipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems.Dyslipidemia and its Treatment in HIV Infection.Rhabdomyolysis after ezetimibe/simvastatin therapy in an HIV-infected patient.Management of dyslipidemia in HIV-infected patients.Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients.Are HIV positive patients resistant to statin therapy?Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers.A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literature.New options in the treatment of lipid disorders in HIV-infected patients.Cardiovascular complications in HIV management: past, present, and future.Lipid management in patients who have HIV and are receiving HIV therapy.Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients.The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges.Management of lipid disorders in patients living with HIV.Drug therapies for HIV-related metabolic disorders.Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy.
P2860
Q28084941-DDDEA939-14E1-4A3D-8BE0-6627118E8D28Q34730407-42802114-E145-40E6-914E-E86EF841E5DDQ35293841-78E15A1D-95CA-480C-8C06-C62E8E07A65DQ35573656-A56A184F-23C8-4645-BE48-65D81E331078Q35643573-83A2D11F-71FB-4A3C-A58F-6F65D14899AAQ35807156-94F2407B-B736-486B-B0C7-B934E8539C6FQ36345121-22ABB8FE-B5D6-4F50-A2EF-26F638D77BADQ36887174-B6EED230-0BB0-4831-88C5-7B0E515AE627Q37199210-AAEB1092-08D8-44D8-A0F2-046D08671C5FQ37271807-75D318C1-708B-4B98-9C9E-919A2E1932B9Q37353573-9A41BDF8-43D9-4CF7-978D-7D22C8C93B02Q37366345-92F97E10-E8B8-4162-8299-95A6A4C42192Q37434889-F7643AE9-2894-49A9-A1C6-B913E189E3F3Q38024436-B4022D9C-7946-41E7-9C31-35EBDE379650Q38344129-4B2AB09A-8B1C-48D3-8F25-DE74BC671E8DQ38837421-0BF4A2E9-FAA8-4F2B-86BF-9C20C905F4CAQ46378097-8CD6708A-A2ED-48B2-929A-D356CBA296D6
P2860
Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Ezetimibe is effective when ad ...... therapy in patients with HIV.
@ast
Ezetimibe is effective when ad ...... therapy in patients with HIV.
@en
type
label
Ezetimibe is effective when ad ...... therapy in patients with HIV.
@ast
Ezetimibe is effective when ad ...... therapy in patients with HIV.
@en
prefLabel
Ezetimibe is effective when ad ...... therapy in patients with HIV.
@ast
Ezetimibe is effective when ad ...... therapy in patients with HIV.
@en
P2093
P2860
P356
P1476
Ezetimibe is effective when ad ...... therapy in patients with HIV.
@en
P2093
Gregory P Bondy
Kevin W Johns
Matthew T Bennett
P2860
P2888
P356
10.1186/1476-511X-6-15
P577
2007-06-13T00:00:00Z
P5875
P6179
1019291616